Research programme: prostate cancer therapy - Genta
Alternative Names: G 20000Latest Information Update: 09 Mar 2015
At a glance
- Originator Genta
- Developer Genta (CEASED)
- Class Small molecules
- Mechanism of Action Cholestenone 5 alpha-reductase inhibitors; Mixed function oxygenase inhibitors; Testosterone congener inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Prostate cancer
Most Recent Events
- 31 May 2004 Discontinued - Preclinical for Prostate cancer in USA (unspecified route)
- 02 Oct 2003 This compound is still in active development (10K filings Dec 2002)
- 22 Aug 2001 Preclinical development for Prostate cancer in USA (Unknown route)